Climate crisis may force us to rethink how we regulate and approve chemicals
Posted July 17, 2019
Chemists raise concerns about what emerging ecological impacts should mean for regulators
Algae blooms are infecting waterways from Lake Erie to the Gulf of Mexico, raising red flags about how global warming is giving the toxic blooms a helping hand.
Toxic blooms are often caused by overloads of synthetic fertilizers that were intended to nourish crops but end up being carried into waterways. Those farm inputs may have been considered suitable in an environment that’s constant but the shifting climate (including heavier rainfall and warming waters) may be making algae blooms worse.Continue Reading...
Social investments for the marginalized take off in North America
Posted January 12, 2017
Acumen’s new U.S. portfolio leads the way
Health is more than health care, according to Healthify, an early-stage social enterprise based in Baltimore that bridges Medicaid patients with critical social services.
The tech company wants to end the causes of negative health that arise outside of clinics. Its software platform gives health care payers, hospitals and providers a tool to search for social services, identify patients’ needs and eligibility for benefits, and coordinate care. Low-income patients get access to housing, nutrition and job search assistance to improve their health and economic stability.Continue Reading...
A different way to R&D
Posted September 27, 2016
Incentivizing big pharma to tackle the less lucrative diseases.
Pharmaceutical giants have never shied away from the chance to make large profits from the sale of their medicines. But what if there was a way to marry corporate and social goals – to delight shareholders and tackle the most pressing global public health epidemics?
An initiative called the Health Impact Fund (HIF) has its eyes set on making medicines affordable and available to all. Supported by leading health scientists, Nobel-prize winning researchers and even former Canadian prime minister Paul Martin, it proposes a system that incentivizes pharmaceutical companies to research and develop drugs for neglected diseases and provides financial rewards to those that significantly reduce the global burden of disease.Continue Reading...